Document is current

Article History

Received: 8 July 2025

Revised: 10 November 2025

Accepted: 28 November 2025

First Online: 18 December 2025

Declarations

:

: All procedures performed in the study ALIENOR were in accordance with the ethical standards of the Bordeaux Ethics Committee (Comité de Protection des Personnes Sud-Ouest et Outre-Mer III, Code 2006/10) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

: An informed, written and signed consent was obtained from all individual participants included in the ALIENOR study.

: Blondy Kayembe-Mulumba, Karen Leffondré, Petra P. Larsen and Émilie Hucteau certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript. Jean-François Korobelnik has received consulting fees from Abbvie, Apellis, Bayer, Eyepoint Pharma, Ocuphire, Ocular Therapeutix, Roche, Théa Pharma, and Carl Zeiss Meditec. Cécile Delcourt has received consulting fees from Allergan, Apellis, Théa Pharma, and Novartis. Marie-Noëlle Delyfer has received consulting fees from Abbvie, Bayer, Horus Pharma, Novartis, Roche and Thea.